The ichroma™ IGRA-TB (Boditech Med Inc., Chuncheon, Republic of Korea) is an automated fluorescent immunoassay-based point-of-care interferon-gamma release assay for detecting latent tuberculosis infection. We evaluated this assay with 408 health care workers, and demonstrated its acceptable performances comparing to QuantiFERON-TB Gold-Plus (QFT-Plus; Qiagen, Germantown, MD). To examine factors associated with continuation of hospital-initiated benzodiazepine receptor agonists (BZRAs) among adults aged ≥65 years, specifically instructions on hospital discharge summaries. This retrospective cohort study involved anonymised electronic record data on prescribing and hospitalisations for 38,229 patients aged ≥65 from forty-four GP practices in Ireland 2011-2016. BZRA initiations were identified among patients with no BZRA prescription in the previous 12 months. Multivariate regression examined whether instructions on discharge messages for hospital-initiated BZRA prescriptions was associated with continuation after discharge in primary care and time to discontinuation. In total, 418 hospital-initiated BZRAs were identified, 48.8% being to males and mean patient age was 79.0 (SD 8.3) years. Almost 60% of these discharge summarieshad some BZRA instructions (e.g. duration). Approximately 40% (n=166) were continued in primary care. Lower age, being prescribed a Z-drug or great number of medicines were associated with higher risk of continuation. Of those continued in primary care, in 98 cases (59.6%) the BZRA was discontinued during follow-up (after a mean 184 days). Presence of instructions was associated with higher likelihood of discontinuation (hazard ratio 1.71, 95%CI 1.11-2.62). Improved communication to GPs after hospital discharge may be important in avoiding long-term BZRA use. Improved communication to GPs after hospital discharge may be important in avoiding long-term BZRA use.There are increasing studies aimed to reveal genomic hallmarks predictive of immune checkpoint blockade (ICB) treatment response, which generated a large number of data and provided an unprecedented opportunity to identify response-related features and evaluate their robustness across cohorts. However, those valuable data sets are not easily accessible to the research community. To take full advantage of existing large-scale immuno-genomic profiles, we developed Immu-Mela (http//bioinfo.vanderbilt.edu/database/Immu-Mela/), a multidimensional immuno-genomic portal that provides interactive exploration of associations between ICB responsiveness and multi-omics features in melanoma, including genetic, transcriptomics, immune cells, and single-cell populations. Immu-Mela also enables integrative analysis of any two genomic features. https://www.selleckchem.com/products/nedisertib.html We demonstrated the value of Immu-Mela by identifying known and novel genomic features associated with ICB response. In addition, Immu-Mela allows users to upload their data sets (unrestricted to any cancer types) and co-analyze with existing data to identify and validate signatures of interest. Immu-Mela reduces barriers between researchers and complex genomic data, facilitating discoveries in cancer immunotherapy. To investigate the treatment effects of Carriere Motion Appliance (CMA) on class II patients. A comprehensive electronic search was performed in PubMed, Scopus, Web of science, ScienceDirect, ProQuest (dissertation and thesis), Google Scholar and ClinicalTrials.gov. All types of clinical trials that contained at least pre- and post-treatment measures of patients treated by CMA were included in this systematic review and meta-analysis. The risk of bias was assessed for all included studies. The considered outcomes were the skeletal, dento-alveolar, soft tissues, temporomandibular joint and airway changes, electromyographic activity and stability. Sixteen studies were included in this systematic review and meta-analysis. The absence of randomized controlled trials which could induce confounding and selection of participant bias is considered the main risk of bias affecting the available studies. Regarding the skeletal changes, no significant effects were appreciated (changes in SNB angle; SMD=-0.13; 95% CI (-0.57, 0.31); P=0.58. Changes in SN-MP; SMD=-0.11; 95% CI (-0.54, 0.33); P=0.64). With respect to the dento-alveolar changes, an increased lower incisor's proclination (L1-MP) was observed; SMD=-0.69; 95% CI (-1.14, -0.24); P=0.003. CMA caused an increase in the airway volume, an increase in the masseter and temporalis muscles activities and a minor relapse of malocclusion after 4-years of follow-up. The results should be taken with caution because only secondary level of evidence was found. The CMA used for the treatment of class II malocclusion did not cause skeletal changes; however, largely dento-alveolar effects were noticed. Prospective randomized clinical trials are highly recommended. The CMA used for the treatment of class II malocclusion did not cause skeletal changes; however, largely dento-alveolar effects were noticed. Prospective randomized clinical trials are highly recommended. Laparoscopic sleeve gastrectomy (LSG) is the most common bariatric operation performed. However, it is not without its drawbacks and patients may develop gastroesophageal reflux (GERD) after LSG. There are limited data available to guide treatment choice for patients suffering these sequelae. This study was undertaken to evaluate the success of conversion to Roux-en-Y gastric bypass (RYGB) in treating GERD symptoms after LSG. Single bariatric center, United States. Analysis of a prospectively maintained clinical database was performed. Outcomes studied included heartburn-related quality of life score (GERD-HRQL), anti-secretory usage, and body mass index (BMI). A total of 54 patients met inclusion criteria during the review period. Of these, 41 patients (76%) underwent conversion for indication including GERD. Mean BMI at conversion was 33.8 ± 5.61 and was found to be significantly reduced at 12 months after conversion (n = 26; 63%; P < .001) and at long-term follow-up (n = 37; 90%) (P ≤ .001; mean follow-up period 33.